Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.59 |
| ▸ | CTSL | P07711 | 4/20 | 0.57 |
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | CTSV | O60911 | 1/20 | 0.57 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053800 | 1.00 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4790890 | 1.00 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL29589864 | 1.00 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4790888 | 1.00 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5105745 | 0.93 | CTSK (0.58) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5105747 | 0.93 | CTSK (0.58) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5096547 | 0.93 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4048060 | 0.93 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5582177 | 0.93 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4770250 | 0.93 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303139-A1 | TARGETING PRIMARY CILIA TO TREAT GLAUCOMA | UNIV INDIANA RES & TECH CORP (US) | 2016-10-20 | — | — | US | claimed |
| US-20150231148-A1 | TARGETING PRIMARY CILIA TO TREAT GLAUCOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-20 | — | — | US | claimed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20240156728-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX OPERATING CO INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4008326-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | Pulmatrix Operating Company, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11173115-B2 | Monovalent metal cation dry powders for inhalation | PULMATRIX OPERATING COMPANY, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3470057-B1 | CATIONIC DRY POWDERS COMPRISING MAGNESIUM SALT | PULMATRIX OPERATING CO INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210121399-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX OPERATING COMPANY, INC. | 2021-04-29 | — | — | US | disclosed |
| US-20210060268-A1 | INHALABLE DRY POWDERS | PULMATRIX OPERATING COMPANY, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10806871-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2013130767-A1 | INHALABLE DRY POWDERS | PULMATRIX, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2621488-A1 | CATIONIC DRY POWDERS | Pulmatrix, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621484-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | Pulmatrix, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012050945-A1 | CATIONIC DRY POWDERS | PULMATRIX, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012044736-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | TRPV4, TRPV2, TRPV3 | CTSK 410/4885CTSL 718/4885CTSS 492/4885 |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | TRPV1, TRPC4, TRPC3 | CTSK 731/4885CTSL 593/4885CTSS 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.